


IN THE CLAIMS:

1. (Currently Amended) A compound of formula:



or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein

**A** represents a substituted or unsubstituted benzene;

B is substituted or unsubstituted carbazolyl;

L is (C<sub>1</sub>-C<sub>4</sub>)alkylene;

X and Y are each independently [[CH or]] CH<sub>2</sub> [[wherein the C is]] optionally substituted with —OR<sup>3</sup>, —N(R<sup>3</sup>)COR<sup>4</sup>, —C(O)NR<sup>3</sup>R<sup>4</sup>, —N(R<sup>3</sup>)CO<sub>2</sub>R<sup>4</sup>, —N(R<sup>3</sup>)C(O)N(R<sup>4</sup>)R<sup>5</sup>, or [[—C(O)]] —C(O)R<sup>4</sup>;

R<sup>1</sup> and R<sup>2</sup> are each independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, —NR<sup>6</sup>C(O)R<sup>5</sup>, —C(O)R<sup>5</sup> and —NR<sup>5</sup>C(O)NR<sup>6</sup>;

each R<sup>b</sup> is selected from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)alkyl, aryl, OR<sup>7</sup>, C(O)R<sup>7</sup> and C(O)NR<sup>7</sup>R<sup>8</sup>;

R<sup>3</sup> and R<sup>4</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>8</sub>)alkyl, hetero(C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, C(O)R', CO<sub>2</sub>R' and C(O)NR'R'';

$R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are independently selected from the group consisting of H,  $(C_1-C_8)$ alkyl,  $C(O)R'''$ ,  $CO_2R'''$ , aryl and aryl $(C_1-C_4)$ alkyl;

optionally, R<sup>7</sup> and R<sup>8</sup> may be combined with the nitrogen to which each is attached to form a 5-, 6- or 7-membered ring;


R', R'' and R''' are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl and aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl; and

the subscript  $p$  is an integer of from 0 to 4.

2. (Original) The compound of Claim 1, wherein the subscript p is 0.

3. (Cancelled)

4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Previously Amended) The compound of Claim 1, wherein **A** represents benzene and B is substituted or unsubstituted 3-carbazolyl.
11. (Cancelled)
12. (Previously Amended) The compound of Claim 1, having the formula (IV):



wherein:


each  $R^a$  is independently selected from the group consisting of halogen, halo( $C_1$ - $C_4$ )alkyl, ( $C_1$ - $C_4$ )alkoxy, aryl( $C_1$ - $C_4$ )alkyl,  $OC(O)R^{17}$ ,  $NR^{17}R^{18}$ ,  $SR^{17}$ , cyano, nitro,  $CO_2R^{17}$ ,  $CONR^{17}R^{18}$ ,  $C(O)R^{17}$ ,  $OC(O)NR^{17}R^{18}$ ,  $NR^{18}C(O)R^{17}$ ,  $NR^{18}CO_2R^{17}$ ,  $NR^{19}C(O)NR^{17}R^{18}$ ,  $S(O)_kR^{17}$ ,  $S(O)_kNR^{17}R^{18}$ ,  $N_3$ , ( $C_4$ - $C_8$ )cycloalkyl, ( $C_5$ - $C_8$ )cycloalkenyl, aryl and heteroaryl, and the subscript k is an integer of from 1 to 2;

$R^{17}$ ,  $R^{18}$  and  $R^{19}$  are independently selected from the group consisting of H, ( $C_1$ - $C_8$ )alkyl, ( $C_1$ - $C_8$ )heteroalkyl, aryl( $C_1$ - $C_4$ )alkyl and aryl; and

the subscript m is an integer of from 0 to 4.

13. (Currently Amended) The compound of Claim 12, wherein X or Y is CH—OH [[CH, wherein the C is substituted with —OH]].
14. (Currently Amended) The compound of Claim 12, wherein Y is CH—OH [[—C<sub>1</sub> alkylene— substituted with —OH]].

15. (Currently Amended) The compound of Claim 12, wherein X is CH—N(R<sup>3</sup>)COR<sup>4</sup> [[CH, wherein the C is substituted with —N(R<sup>3</sup>)COR<sup>4</sup>]].
16. (Currently Amended) The compound of Claim 12, wherein X is CH—N(R<sup>3</sup>)COR<sup>4</sup> [[CH, wherein the C is substituted with —N(R<sup>3</sup>)COR<sup>4</sup>]] and Y is CH—OH [[—C<sub>1</sub> alkylene— substituted with —OH]].
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Currently Amended) The compound of Claim 1 having the formula (V):



V


wherein

each [[Ra]] R<sup>a</sup> is independently halogen, halo(C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, OC(O)R<sup>17</sup>, NR<sup>17</sup>R<sup>18</sup>, SR<sup>17</sup>, cyano, nitro, CO<sub>2</sub>R<sup>17</sup>, CONR<sup>17</sup>R<sup>18</sup>, C(O)R<sup>17</sup>, OC(O)NR<sup>17</sup>R<sup>18</sup>, NR<sup>18</sup>C(O)R<sup>17</sup>, NR<sup>18</sup>CO<sub>2</sub>R<sup>17</sup>, NR<sup>19</sup>C(O)NR<sup>17</sup>R<sup>18</sup>, S(O)<sub>k</sub>R<sup>17</sup>, S(O)<sub>k</sub>NR<sup>17</sup>R<sup>18</sup>, N<sub>3</sub>, (C<sub>4</sub>-C<sub>8</sub>)cycloalkyl, (C<sub>5</sub>-C<sub>8</sub>)cycloalkenyl, aryl or heteroaryl, wherein R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl and aryl, and the subscript k is an integer of from 1 to 2; and

the subscript m is an integer of from 0 to 4.

21. (Original) The compound of Claim 20, wherein R<sup>1</sup> and R<sup>2</sup> are H.

22. (Original) The compound of Claim 1, having the formula:



wherein

$R^{11}$  is selected from the group consisting of H, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, heteroaryl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, (C<sub>5</sub>-C<sub>8</sub>)cycloalkenyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloheteroalkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloheteroalkyl-alkyl, C(O)R<sup>12</sup>, CO<sub>2</sub>R<sup>12</sup>, C(O)NR<sup>12</sup>R<sup>13</sup>, S(O)<sub>k</sub>R<sup>12</sup> and S(O)<sub>k</sub>NR<sup>12</sup>R<sup>13</sup>;

each R<sup>c</sup> is independently selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, halo(C<sub>1</sub>-C<sub>8</sub>)alkyl, halogen, CN, NO<sub>2</sub>, OR<sup>14</sup>, SR<sup>14</sup>, NR<sup>14</sup>R<sup>15</sup>, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, (C<sub>5</sub>-C<sub>8</sub>)cycloalkenyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloheteroalkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloheteroalkyl-alkyl, C(O)R<sup>14</sup>, CO<sub>2</sub>R<sup>14</sup>, C(O)NR<sup>14</sup>R<sup>15</sup>, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, heteroaryl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, S(O)<sub>k</sub>R<sup>14</sup>, S(O)<sub>k</sub>NR<sup>14</sup>R<sup>15</sup>, N(R<sup>15</sup>)S(O)<sub>k</sub>R<sup>14</sup>, OC(O)R<sup>14</sup>, OCO<sub>2</sub>R<sup>14</sup>, OC(O)NR<sup>14</sup>R<sup>15</sup>, N(R<sup>16</sup>)C(O)NR<sup>14</sup>R<sup>15</sup>, N(R<sup>15</sup>)C(O)R<sup>14</sup> and N(R<sup>15</sup>)CO<sub>2</sub>R<sup>14</sup>;


optionally, any two adjacent R<sup>c</sup> groups may be combined to form a fused aryl ring or (C<sub>5</sub>-C<sub>8</sub>)cycloalkyl ring;

R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl and aryl;

the subscript q is an integer of from 0 to 7; and

the subscript k is an integer of from 1 to 2.

23. (Original) The compound of Claim 22, having the formula:



wherein

each R<sup>a</sup> is independently selected from the group consisting of halogen,


halo(C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, OC(O)R<sup>17</sup>, NR<sup>17</sup>R<sup>18</sup>, SR<sup>17</sup>, cyano, nitro, CO<sub>2</sub>R<sup>17</sup>, CONR<sup>17</sup>R<sup>18</sup>, C(O)R<sup>17</sup>, OC(O)NR<sup>17</sup>R<sup>18</sup>, NR<sup>18</sup>C(O)R<sup>17</sup>, NR<sup>18</sup>CO<sub>2</sub>R<sup>17</sup>, NR<sup>19</sup>C(O)NR<sup>17</sup>R<sup>18</sup>, S(O)<sub>k</sub>R<sup>17</sup>, S(O)<sub>k</sub>NR<sup>17</sup>R<sup>18</sup>, N<sub>3</sub>, (C<sub>4</sub>-C<sub>8</sub>)cycloalkyl, (C<sub>5</sub>-C<sub>8</sub>)cycloalkenyl, aryl and heteroaryl;

R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl and aryl;

the subscript m is an integer of from 0 to 4; and

each subscript k is an integer of from 1 to 2.

24. (Previously Amended) The compound of any one of Claims 1, 20 and 23, wherein L is methylene.
25. (Currently Amended) The compound of Claim 23, having the formula (**Xa**):















**Xa**

wherein


L is methylene; and

X and Y are each independently CH<sub>2</sub> [[selected from -(C<sub>1</sub>-C<sub>2</sub>)alkylene-, wherein C<sub>1</sub> or C<sub>2</sub> is]] optionally substituted with -OR<sup>3</sup>, -N(R<sup>3</sup>)COR<sup>4</sup>, -C(O)NR<sup>3</sup>R<sup>4</sup> or -N(R<sup>3</sup>)C(O)N(R<sup>4</sup>)R<sup>5</sup>.

26. (Currently Amended) The compound of Claim [[25]] 23, having a formula selected from the group consisting of:



27. (Previously Amended) A compound of formula:



VII

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein

$R^{20}$  and  $R^{23}$  independently represent H or  $OR^3$ ;

$R^{21}$  and  $R^{22}$  independently represent H,  $OR^3$ ,  $N(R^3)COR^4$ ,  $C(O)NR^3R^4$ ,  $N(R^3)CO_2R^4$ ,  $N(R^3)C(O)N(R^4)R^5$ ,  $N(R^3)R^4$ ,  $C(O)N(R^3)R^4$ ,  $N(R^3)C(O)R^4$ ,  $(CH_2)C(O)N(R^3)(R^4)$ ,  $(CH_2)CO_2R^3$ , or  $(C_1-C_4)alkyl$ ;

$R^{11}$  represents H,  $(C_1-C_4)alkyl$ ,  $(C_2-C_8)alkenyl$ ,  $(C_2-C_8)alkynyl$ ,  $(C_1-C_8)heteroalkyl$ , aryl, aryl $(C_1-C_4)alkyl$ , heteroaryl, heteroaryl $(C_1-C_4)alkyl$ ,  $(C_3-C_8)cycloalkyl$ ,  $(C_5-C_8)cycloalkenyl$ ,  $(C_3-C_8)cycloalkyl-alkyl$ ,  $(C_3-C_8)cycloheteroalkyl$ ,  $(C_3-C_8)cycloheteroalkyl-alkyl$ ,  $C(O)R^{12}$ ,  $CO_2R^{12}$ ,  $C(O)NR^{12}R^{13}$ ,  $S(O)_kR^{12}$  or  $S(O)_kNR^{12}R^{13}$ ;


$R^{12}$  and  $R^{13}$  independently represent H,  $(C_1-C_8)alkyl$ ,  $(C_1-C_8)heteroalkyl$ , aryl $(C_1-C_4)alkyl$  or aryl;

$R^3$  and  $R^4$  independently represent H,  $(C_1-C_8)alkyl$ , hetero $(C_1-C_8)alkyl$ , aryl, aryl $(C_1-C_4)alkyl$ ,  $C(O)R'$ ,  $CO_2R'$  or  $C(O)NR'R''$ ; and

$R'$ ,  $R''$  and  $R'''$  are independently selected from the group consisting of H,  $(C_1-C_8)alkyl$ , aryl and aryl $(C_1-C_4)alkyl$ .

28. (Original) The compound of Claim 27, wherein  $R^{20}$  and  $R^{23}$  each represent H,  $R^{22}$  represents OH, and  $R^{21}$  represents  $N(R^3)C(O)R^4$ .
29. (Original) The compound of Claim 27, wherein  $R^{20}$  represents OH, and  $R^{22}$  and  $R^{23}$  each represent H, and  $R^{21}$  represents  $C_2 alkyl$ .
30. (Original) The compound of Claim 27, wherein  $R^{20}$ ,  $R^{22}$ , and  $R^{23}$  each represent H and  $R^{21}$  represents  $N(R^3)C(O)R^4$ .
31. (Original) The compound of Claim 27, wherein  $R^{20}$ ,  $R^{22}$ , and  $R^{23}$  each represent H and  $R^{21}$  represents  $(CH_2)CO_2R^3$ .
32. (Original) The compound of Claim 27, wherein  $R^{20}$ ,  $R^{22}$ , and  $R^{23}$  each represent H and  $R^{21}$  represents  $(CH_2)C(O)N(R^3)(R^4)$ .

33. (Original) The compound of Claim 27, having a formula that is selected from the group consisting of:



34. (Cancelled)  
 35. (Cancelled)  
 36. (Cancelled)  
 37. (Cancelled)  
 38. (Cancelled)  
 39. (Cancelled)



40. (Cancelled)
41. (Cancelled)
42. (Previously Amended) The compound of Claim 25, wherein L is methylene.
43. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 1.
44. (Currently Amended) A method of treating a condition or disorder selected from the group consisting of obesity, type II diabetes, hypertension, hyperuricemia, stroke, dyslipidemia, coronary artery disease, hypercholesterolemia and atherosclerosis[.] comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Claim 1.
45. (Cancelled)
46. (Cancelled)
47. (Cancelled)
48. (Cancelled)
49. (Cancelled)
50. (Cancelled)
51. (Cancelled)
52. (Cancelled)
53. (Cancelled)
54. (Cancelled)
55. (Cancelled)
56. (Cancelled)
57. (Cancelled)

Express Mail No.: EV 456 920 972 US

58. (Cancelled)

59. (Cancelled)

60. (Cancelled)

61. (Cancelled)

62. (Cancelled)

63. (Cancelled)

64. (Cancelled)

65. (Cancelled)